Markets:

Overview

News

Currencies

International

Treasuries

Sutro Biopharma, Inc. - Common Stock (NQ:STRO)

0.8481 -0.0319 (-3.63%)

Streaming Delayed Price Updated: 2:38 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sutro Biopharma, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Sutro Biopharma Collapses; Why One Analyst Remains Bullish On Its Chances In Cancer ↗

January 06, 2022

Sutro Biopharma could still find a place for itself in ovarian cancer treatment.

Via Investor's Business Daily

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

January 06, 2022

Gainers Eargo (NASDAQ:EAR) stock increased by 50.0% to $6.84 during Thursday's regular session. The current volume of 90.4 million shares is 5474.6% of Eargo's...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

January 06, 2022

On Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows: Sea (NYSE:SE) is the largest company in terms of market cap to set a new 52-week low this...

Via Benzinga

33 Stocks Moving In Thursday's Mid-Day Session ↗

January 06, 2022

Gainers Eargo, Inc. (NASDAQ: EAR) shares jumped 50.8% to $6.88 after the company announced the Department of Justice confirmed to it that the previously-announced criminal probe...

Via Benzinga

The Daily Biotech Pulse: Lilly Strikes Neurological R&D Collaboration, Valneva Confirms Vaccine Timelines, Biohaven Gains On Strong Migraine Drug Sales ↗

January 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Illumina Announces Co-Development Partnership With SomaScan For Accelerating...

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets ↗

January 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon,...

Via Benzinga

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline ↗

August 18, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Week Ahead In Biotech (Jan. 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week ↗

January 02, 2022

Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. Here are the key catalysts that can sway biotech stocks in the unfolding week.

Via Talk Markets

The Week Ahead In Biotech (Jan 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week ↗

January 02, 2022

Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. On the regulatory front, the Food And Drug Administration...

Via Benzinga

Week In Review: Tasly Pharma Acquires Sutro ADC In $385 Million Deal ↗

January 01, 2022

Tasly Pharma acquired Greater China rights to an antibody-drug conjugate from Sutro Biopharma in a deal worth up to $385 million. Sutro will receive an upfront payment of $40 million and be eligible...

Via Talk Markets

Sutro Biopharma Earnings Perspective: Return On Capital Employed ↗

November 11, 2021

Benzinga Pro data, Sutro Biopharma (NASDAQ:STRO) reported Q3 sales of $8.52 million. Earnings fell to a loss of $34.67 million, resulting in a 253.64% decrease from last quarter...

Via Benzinga

Week In Review: Hansoh Signs $456 Million Deal For siRNA Products ↗

October 16, 2021

Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea's OliX Pharma. Hansoh will make an upfront payment of $6.5 million and up to...

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2021 ↗

November 17, 2021

Upgrades According to Williams Capital, the prior rating for On Holding AG (NYSE:

Via Benzinga

Merck, Sutro Biopharma Extends Cytokine Derivative Research Program ↗

September 30, 2021

Merck & Co Inc (NYSE: MRK) has extended the research term by two years for the first cytokine derivative program under a 2018 agreement with Sutro...

Via Benzinga

Sutro Biopharma Earnings Perspective: Return On Capital Employed ↗

September 20, 2021

According to Benzinga Pro data, during Q2, Sutro Biopharma (NASDAQ:STRO) posted sales of $28.05 million. Earnings were up 48.42%, but Sutro Biopharma still reported an overall...

Via Benzinga

Sutro Biopharma's Ovarian Cancer Candidate Fast Tracked In US ↗

August 18, 2021

The FDA has granted Fast Track designation to Sutro Biopharma Inc's (NASDAQ: STRO) STRO-002 for ovarian cancer. The designation covers platinum-resistant...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 18, 2021 ↗

June 18, 2021

Upgrades According to JP Morgan, the prior rating for Orion Engineered Carbons SA (NYSE:

Via Benzinga

Sutro Biopharma Receives Undisclosed Milestone Payment Under Bispecific ADC Collaboration with Merck ↗

June 01, 2021

Sutro Biopharma Inc (NASDAQ: STRO) has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.